Full metadata record
DC FieldValueLanguage
dc.contributor.authorJOSEFSSON ANDERSen_GB
dc.contributor.authorNEDROW JESSIEen_GB
dc.contributor.authorPARK SUNJUen_GB
dc.contributor.authorBRUCHERTSEIFER FRANKen_GB
dc.contributor.authorMORGENSTERN ALFREDen_GB
dc.contributor.authorSGOUROS G.en_GB
dc.contributor.authorHOBBS ROBERT F.en_GB
dc.description.abstractThere has been increasing interest in the use alpha-particle emitting radionuclides to combat cancer, especially in metastasized disease. The short range of the emitted alpha-particles combined with the high LET makes them effective against single cells, cell clusters and solid tumors. Studies have shown that the main part of the absorbed dose to the kidneys when using 225Ac labeled antibodies originates from the free daughter 213Bi, which is generated from 225Ac in the rest of the body. Furthermore, the dosimetry has been well qualitatively characterized using the macro-to-micro (M2M) small scale methodology. In this study we examine how the tumor burden affects the absorbed dose to the kidneys from both the 225Ac labeled antibody and the free daughter 213Bi in a transgenic immunocompetent mouse model applying M2M and extrapolate to human use.en_GB
dc.description.sponsorshipJRC.G.I.5-Advanced Nuclear Knowledgeen_GB
dc.publisherEuropean Commission - Joint Research Centreen_GB
dc.titleThe impact of tumor burden on the absorbed dose to the kidneys from Actinium-225 labeled antibody therapy in a murine model and predicted dosimetric impact for human clinical useen_GB
dc.typeArticles in periodicals and booksen_GB
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.